Effects of estrogen deprivation due to breast cancer treatment

被引:24
作者
Angelopoulos, N
Barbounis, V
Livadas, S
Kaltsas, D
Tolis, G
机构
[1] Hippokrateion Hosp Greece, Div Endocrinol & Metab, Endocrine Dept, Athens 11527, Greece
[2] St Savas Oncol Hosp, Dept Med Oncol 2, Athens 11522, Greece
关键词
D O I
10.1677/erc.1.00783
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is one of the main life-threatening diseases that a woman may have to face during her lifetime. The increasing incidence of breast neoplasia reported over the last few decades has led to widespread screening of women resulting in early diagnosis. One common but challenging question for most doctors, after the surgical excision of the lesion, is determination of the ideal adjuvant therapy for their patients for the achievement of maximum life expectancy with the best quality of life. Since the beginning of the last century, the knowledge that breast cancer arises from hormone-responsive tissues has long made use of hormone-blocking agents in the beneficial treatment of breast neoplasia. The discovery of new molecules with endocrine actions has rendered the use of adjuvant therapy in a tailor-made pattern too complicated, as these agents have a different mode of action, different adverse effects and probably different indications. The aim of the present review is to clarify these issues, analyzing the mechanism of action of available drugs and their actions on specific areas of uncertainty: cognitive function, cardiovascular system, urogenital tract, bone metabolism, weight gain, hot flushes and premature menopause. Regarding the efficacy of adjuvant therapy, there has been particular focus on the multiple hormonal-induced consequences of each regimen in order to provide the clinician with the available data for choosing the ideal therapy for the patient.
引用
收藏
页码:523 / 535
页数:13
相关论文
共 99 条
[71]  
Pink JJ, 1996, CANCER RES, V56, P2321
[72]   Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women [J].
Powles, T ;
Hickish, T ;
Kanis, JA ;
Tidy, A ;
Ashley, S .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (01) :78-84
[73]   Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer [J].
Powles, T ;
Paterson, S ;
Kanis, JA ;
McCloskey, E ;
Ashley, S ;
Tidy, A ;
Rosenqvist, K ;
Smith, I ;
Ottestad, L ;
Legault, S ;
Pajunen, M ;
Nevantaus, A ;
Männistö, E ;
Suovuori, A ;
Atula, S ;
Nevalainen, J ;
Pylkkänen, L .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (15) :3219-3224
[74]   Drug therapy: Selective estrogen-receptor modulators - Mechanisms of action and application to clinical practice [J].
Riggs, BL ;
Hartmann, LC .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :618-629
[75]   CARDIAC AND THROMBOEMBOLIC MORBIDITY AMONG POSTMENOPAUSAL WOMEN WITH EARLY-STAGE BREAST-CANCER IN A RANDOMIZED TRIAL OF ADJUVANT TAMOXIFEN [J].
RUTQVIST, LE ;
MATTSSON, A .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (17) :1398-1406
[76]   Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients [J].
Saarto, T ;
Blomqvist, C ;
Valimaki, M ;
Makela, P ;
Sarna, S ;
Elomaa, I .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) :1341-1347
[77]   Antiatherogenic effects of adjuvant antiestrogens: A randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer [J].
Saarto, T ;
Blomqvist, C ;
Ehnholm, C ;
Taskinen, MR ;
Elomaa, I .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) :429-433
[78]   Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial [J].
Saarto, T ;
Blomqvist, C ;
Virkkunen, P ;
Elomaa, I .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (01) :10-17
[79]   VENOUS AND ARTERIAL THROMBOSIS IN PATIENTS WHO RECEIVED ADJUVANT THERAPY FOR BREAST-CANCER [J].
SAPHNER, T ;
TORMEY, DC ;
GRAY, R .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (02) :286-294
[80]  
Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO